Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20795)	5/14/1998 7:57:00 PM
From: Sleepman	Respond to of 32384

Henry: A couple of things. I hope that you are correct that LGND has a pretty good idea of what the FDA will do with ONTAK, but my recent experience in TXB as well as my knowledge of the FDA in general leads me to believe that one cannot rely on these "feelings." Perhaps that is why the market has not reacted more positively about the takeover. I personally think that the Seragen approach, as I understand it, is a very promising approach to deal with a number of medical conditions including malignancy and latent infections such as HIV. Another thing that I do not entirely understand is this thread's facination with tamoxifen and the comparisons to targretin. These two drugs are very different and work in entirely different mechanisms. They both may have chemopreventative properties, but the potential of targretin and its derivatives is so much broader than tamoxifen--due to the differing mechanism. I cannot remember the toxicity data from targretin, but as I recall, it is not too bad. If that holds up in further testing, this can certainly be a winner. If not, well, it may still be approvable as an effective antineoplastic. I am a huge fan of Ligand. At Cancer meetings, they are all over the place. I think that in the near future we are in for significant appreciation. I hope I am right. I was wrong (on the sort term, but still have longer term hopes) on TXB. Dan